Séminaire - David Blum "Adenosine A2A receptors: a neuro-glial effector in Alzheimer's Disease and Tauopathies"

Détails de la réservation

• Le : 8 November 2019
• De : 11 h 30
• à : 13 h 00
• Salle : Amphi Centre Broca Nouvelle - Aquitaine

Détails de l'évènement

David Blum

UMR Inserm UMR-S1172 – Lille

 

 

"Adenosine A2A receptors: a neuro-glial effector in Alzheimer's Disease and Tauopathies"

 

Abstract :

Consumption of caffeine, a non-selective antagonist of adenosine A_2A receptor (A_2AR), mitigates cognitive decline during ageing, reduces Alzheimer’s disease (AD) risk in Humans, and also decreases amyloid and Tau pathologies in AD transgenic mouse models. In line, selective A_2AR blockade improves memory and pathology in transgenic models mimicking Tau and amyloid lesions. These data not only support A_2A receptor as a valuable target in AD but also suggest that A_2A receptors are involved in the pathophysiological development of the disease. Beneficial effects of caffeine and A_2AR antagonists are presumably ascribed to the normalization of dysregulated A_2AR activity. Indeed, brains of aged and AD individuals but also AD models are characterized by an abnormal upsurge of A_2ARs, being of neuronal and astrocytic origin. However, respective impact of neuronal and astrocytic A_2AR dysregulations towards development of cognitive deficits and AD lesions remains largely unknown. Our current project is to provide new insights on the impact of neuronal and astroglial gain of A_2AR function towards cognition and brain lesions in transgenic models of AD.

Invité par : Eric Boué-Grabot

Responsable

• Nom : BOUE-GRABOT ERIC